Thomas R. Cox, Aug 2012
My review on the potential of therapeutic targeting of the Lysyl Oxidase (LOX) family in cancer has just been published in this months edition of Nature Reviews Cancer.
Our review discusses the recent breakthroughs which have been made in understanding the role of Lysyl Oxidase and its related family members in cancer initiation, progression and metastasis, and the progress which is being made into targeting these molecules in cancer treatment
The therapeutic targeting of extracellular proteins is becoming hugely attractive in light of evidence implicating the tumour microenvironment as pivotal in all aspects of tumour initiation and progression. Members of the lysyl oxidase (LOX) family of proteins are secreted by tumours and are the subject of much effort to understand their roles in cancer. In this Review we discuss the roles of members of this family in the remodelling of the tumour microenvironment and their paradoxical roles in tumorigenesis and metastasis. We also discuss how targeting this family of proteins might lead to a new avenue of cancer therapeutics.
Barker HE*, Cox TR* and Erler JT. The rationale for targeting the LOX family in cancer.
Nature Reviews Cancer, 12, 540-552 (August 2012) | doi:10.1038/nrc3319
* These authors contributed equally